건강 지식

Atrial Fibrillation: Why It Raises Stroke Risk Fivefold, How to Score CHA₂DS₂-VA, and Choosing Anticoagulants When Kidneys Are Weak

Beyond CKD 10 분 소요

Atrial fibrillation is the most common sustained arrhythmia; it raises stroke risk about fivefold and AF strokes tend to be more severe. Based on the 2024 ESC and 2023 ACC/AHA guidelines: symptoms and self-detection, stroke-risk scoring, DOACs vs warfarin, and the special considerations for CKD and dialysis.

목차
  1. What atrial fibrillation is
  2. Symptoms: some people feel nothing
  3. Stroke risk: CHA₂DS₂-VA
  4. Anticoagulants: DOACs before warfarin
  5. Choosing when kidney function is reduced
  6. Controlling the heartbeat: rhythm vs rate
  7. Risk factors you can change
  8. When to seek care immediately
  9. Questions to ask your doctor
  10. References

What atrial fibrillation is

In atrial fibrillation (AF) the atria lose organised contraction and "quiver" at 300–600 times a minute while the ventricles beat irregularly. About 59 million people have AF worldwide, and prevalence rises steeply with age — roughly 1 in 10 over 80 [1][2].

AF itself is rarely fatal; the danger is blood pooling in the atrium and clotting. A clot travelling to the brain causes an ischaemic stroke. AF raises stroke risk about fivefold, and AF-related strokes are typically larger, more disabling and more often fatal [1][2].

Symptoms: some people feel nothing

  • Palpitations (fast, irregular, "skipped" beats)
  • Breathlessness, fatigue, reduced exercise capacity
  • Dizziness, chest discomfort
  • Around one third have no symptoms; the first sign may be a stroke [1]

Self-detection

  • Pulse check: radial pulse at the wrist for 30 seconds; a completely irregular rhythm warrants an ECG.
  • Smartwatches/bands: AF detection on Apple Watch, Fitbit and others is reasonably accurate, but a positive result must be confirmed by ECG and a negative does not rule AF out [1][2].
  • Opportunistic screening (pulse or single-lead ECG) is recommended from age 65 [1].

Stroke risk: CHA₂DS₂-VA

The 2024 ESC guideline simplified CHA₂DS₂-VASc to CHA₂DS₂-VA, dropping the sex point [1]:

Item Points
C Heart failure 1
H Hypertension 1
A₂ Age ≥75 2
D Diabetes 1
S₂ Prior stroke/TIA/thromboembolism 2
V Vascular disease (MI, peripheral artery disease, aortic plaque) 1
A Age 65–74 1
  • ≥2: anticoagulation recommended.
  • 1: anticoagulation should be considered.
  • 0: not recommended (risk lower than bleeding risk).

The 2023 US guideline still uses CHA₂DS₂-VASc (with 1 point for female sex) and thresholds of ≥2 men / ≥3 women [2].

Note: CKD is not in the score, yet CKD raises both stroke and bleeding risk [2][5].

Anticoagulants: DOACs before warfarin

Antiplatelets (aspirin) do not prevent AF stroke; guidelines explicitly advise against aspirin alone [1][2].

Drug Notes
DOACs: apixaban, rivaroxaban, edoxaban, dabigatran Preferred. In large trials non-inferior or superior to warfarin, with about half the intracranial bleeding, and no routine blood monitoring [1][2][3]
Warfarin For mechanical valves, moderate–severe mitral stenosis, or when DOACs are unsuitable (e.g. dialysis — see below). Needs INR 2.0–3.0 with time in range >70% [1][2]

Key DOAC points [3]:

  • Doses depend on age, weight and kidney function; never under-dose "to be safe" — it increases stroke without reducing major bleeding.
  • Interactions with rifampicin, some anti-epileptics and strong CYP3A4/P-gp inhibitors; transplant recipients on tacrolimus/ciclosporin need particular care — use this site's interaction lookup and ask your pharmacist.
  • Missed dose? Once-daily drugs can be taken within 12 hours; twice-daily within 6 hours; otherwise skip — never double [3].

Bleeding risk

A HAS-BLED score ≥3 flags high bleeding risk but is not a reason to withhold anticoagulation; it prompts fixing modifiable factors: BP control, stopping unnecessary NSAIDs/aspirin, limiting alcohol, fall prevention [1][2].

Choosing when kidney function is reduced

The commonest question from kidney patients, and the area with the least evidence [2][3][5]:

eGFR Guidance
≥50 Standard DOAC dose
30–49 DOACs usable with label-based reduction (e.g. rivaroxaban 15 mg, edoxaban 30 mg; apixaban drops to 2.5 mg bid only if 2 of 3: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL)
15–29 Weak evidence; reduced-dose apixaban or rivaroxaban may be considered (US labels allow; dabigatran contraindicated in Europe)
<15 or dialysis Very few randomised trials. US label permits apixaban (observational data plus small RENAL-AF and AXADIA trials); most DOACs are not approved in Europe. Warfarin's benefit in dialysis is uncertain and it may accelerate vascular calcification. Decisions must be individualised jointly by cardiology and nephrology; left-atrial-appendage occlusion is an alternative [2][4][5]

Also note that DOAC labels use Cockcroft-Gault creatinine clearance (CrCl), which can differ from CKD-EPI eGFR, especially at extremes of body weight [3].

Controlling the heartbeat: rhythm vs rate

  • Rate control (beta-blockers, diltiazem/verapamil, digoxin): keep the resting rate <110 bpm, usually sufficient.
  • Rhythm control (antiarrhythmics, cardioversion, catheter ablation): EAST-AFNET 4 showed that early rhythm control within a year of diagnosis reduces cardiovascular events [6]; ablation beats drugs for symptomatic paroxysmal AF.
  • Whatever the strategy, anticoagulation continues according to the score, regardless of whether sinus rhythm returns [1][2].

Drug cautions for kidney patients

  • Diltiazem/verapamil interact seriously with tacrolimus/ciclosporin (transplant).
  • Digoxin is renally cleared: reduce the dose and monitor levels in CKD; low potassium increases toxicity.
  • Sotalol and dofetilide are renally cleared; contraindicated or dose-adjusted at low eGFR [2].

Risk factors you can change

The 2024 ESC guideline makes risk-factor management the foundation of care (the "C" of AF-CARE) [1]: BP control, weight loss (10% loss in BMI ≥27 markedly reduces recurrence), limiting alcohol (>3 drinks/week increases AF), treating sleep apnoea, controlling diabetes, regular exercise.

When to seek care immediately

Call emergency services (stroke warning FAST):

  • Face drooping, Arm weakness on one side, Speech slurred, Time to call — even if symptoms resolve in minutes (TIA).
  • Heart rate >150 with chest pain, fainting or breathlessness.
  • On anticoagulants: black stools, vomiting blood, persistent blood in urine, severe headache after a head knock.

Same day: new persistent palpitations or a completely irregular pulse; several missed anticoagulant doses.

Questions to ask your doctor

  1. What is my CHA₂DS₂-VA score?
  2. For my kidney function (eGFR/CrCl), which anticoagulant and dose fit best?
  3. Do my other medicines (especially anti-rejection drugs and painkillers) interact with it?
  4. Am I a candidate for catheter ablation?
  5. If I need surgery or a dental extraction, how do I pause and restart the anticoagulant?

References

  1. Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2024;45(36):3314–3414. https://doi.org/10.1093/eurheartj/ehae176
  2. Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for Atrial Fibrillation. Circulation. 2024;149(1):e1–e156. https://doi.org/10.1161/CIR.0000000000001193
  3. Steffel J, et al. 2021 EHRA Practical Guide on NOACs in atrial fibrillation. Europace. 2021;23(10):1612–1676. https://doi.org/10.1093/europace/euab065
  4. Pokorney SD, et al. RENAL-AF. Circulation. 2022;146(23):1735–1745. https://doi.org/10.1161/CIRCULATIONAHA.121.054990
  5. KDIGO 2024 Clinical Practice Guideline for CKD. Kidney Int. 2024;105(4S):S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
  6. Kirchhof P, et al. EAST-AFNET 4. N Engl J Med. 2020;383(14):1305–1316. https://doi.org/10.1056/NEJMoa2019422

This article compiles publicly available medical information for educational purposes only. It is not medical advice and has not been reviewed by a practising physician. For any health or medication question, consult a qualified professional. For chest pain, sudden breathlessness, one-sided weakness or slurred speech, call your local emergency number or go to the emergency department immediately.

변경 기록

  • 初版:依 2024 ESC 心房顫動指引、2023 ACC/AHA/ACCP/HRS 指引、KDIGO 2024 CKD 指引整理;抗凝血劑劑量依各藥仿單。
공유:
다른 언어로 읽기:English日本語繁體中文

Where to go next

Related knowledge

Understand the related tests

Lived experience

독립적으로 운영하며, 건강 정보를 더 쉽게 이해하고 찾을 수 있도록 노력합니다.

BeyondCKD는 신장 건강과 통합 케어를 중심으로 하는 독립 건강 정보 플랫폼입니다. 의학 연구, 진료 지침, 실용적인 자료를 정리하여 흩어진 정보를 이해하기 쉽고 찾기 쉬우며 바로 활용할 수 있는 콘텐츠로 만들어, 다양한 건강 단계에 있는 분들이 더 근거 있는 선택을 하도록 돕습니다.

본 사이트는 의료 관련 업체의 유료 게재를 받지 않으며, 상업적 제휴가 추천 내용을 좌우하지 않습니다. 운영은 명확히 표시된 광고와 제휴 링크로 지원될 수 있으며, 모든 협력은 투명성 원칙에 따라 공개하고 콘텐츠 판단의 근거로 삼지 않습니다. 자세한 내용은제휴 마케팅 공개。

콘텐츠 정리, 자료 유지, 도구 개발, 다국어 업데이트에는 지속적인 시간과 자원이 필요합니다. BeyondCKD가 도움이 되었다면, 이러한 자료가 계속 유지되고 더 많은 사람에게 전해질 수 있도록 후원해 주시면 감사하겠습니다.

후원하기